Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma.

Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. Abstract Text:

    azizbek ramankulovAzizbek Ramankulov,michael leinMichael Lein,glen kristiansenGlen Kristiansen,hellmuth-a meyerHellmuth-A Meyer,stefan a loeningStefan A Loening,klaus jungKlaus Jung,azizbek ramankulovAzizbek Ramankulov,michael leinMichael Lein,glen kristiansenGlen Kristiansen,hellmuth-a meyerHellmuth-A Meyer,stefan a loeningStefan A Loening,klaus jungKlaus Jung,

    PURPOSE: To evaluate diagnostic and prognostic significance of plasma osteopontin (OPN) in patients with renal cell carcinoma (RCC). METHODS: The retrospective study included 80 patients with RCC (pN0M0, n = 32; pN1M0, n = 11; M1, and n = 37), and 52 healthy controls (27 females and 25 males). OPN, the bone marker bone-specific alkaline phosphatase (bALP) and carboxyterminal telopetide of type-I collagen (ICTP), and the enzymes alanine aminotransferase (ALAT), and gamma-glutamyltransferase (GGT) were evaluated together with Memorial Sloan-Kettering Cancer Center (MSKCC) laboratory parameters. Data were analyzed by receiver-operating characteristics (ROC), survival analysis, and Cox proportional hazards regression model. RESULTS: OPN and ICTP levels in RCC patients with distant metastases were significantly elevated (medians 115 and 4.7 microg/l, P < 0.001) compared to those without metastases (31.1 and 2.5 microg/l) and controls (28.9 and 2.1 microg/l) but did not differ between patients with bone or non-bone metastases. Both bALP and ALAT were not different between all study groups, while GGT was only increased in patients with non-bone metastases. In ROC analysis, OPN showed the best discrimination between patients with and without metastases (area under the curve: 0.888). High OPN values were associated with poor survival (Kaplan-Meier analysis, log-rank test, P = 0.002). Multivariate Cox regression with forward and backward stepwise elimination confirmed plasma OPN as independent predictive survival factor in RCC patients. CONCLUSIONS: Our results show that high plasma OPN levels are associated with distant metastases and poor survival in RCC patients. The use of OPN as potential marker to monitor new treatment strategies in patients with advanced RCC should be evaluated in prospective studies.

    Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. Publishing Authors By Initials

    a ramankulovA Ramankulov,m leinM Lein,g kristiansenG Kristiansen,ha meyerHA Meyer,sa loeningSA Loening,k jungK Jung,a ramankulovA Ramankulov,m leinM Lein,g kristiansenG Kristiansen,ha meyerHA Meyer,sa loeningSA Loening,k jungK Jung,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. Journal Published:

    PUBLICATION TYPE: Research Support, Non-U.S. Gov

    Journal: Journal of cancer research and clinical oncology

    VOLUME: 133

    Page Numbers: 643-52

    Journal Abbreviation: J. Cancer Res. Clin. Oncol.

    ISSN: 0171-5216

    DAY: 4

    MONTH: 05

    YEAR: 2007

    Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 7902060

    Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma.

    AFFILIATION: Department of Urology, University Hospital Charité, Charité-University Medicine Berlin, Campus Charité Mitte, Schumannstrasse 20/21, 10098 Berlin, Germany.

    Country: Germany

    Germany Research PublicationGermany Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: J Cancer Res Clin Oncol

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News